SuperworthEmergent BioSolutions EBS
- Market cap
- $319.4M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.4×
- EV/EBIT
- 6.4×
- Revenue, 12 months
- $770.2M
- −10% on a year ago
- Net margin
- −23.0%
- Free cash flow yield
- 26.9%
Emergent BioSolutions trades at 0.4× sales. Its trailing earnings are negative, so it has no PE. Revenue was $770.2M over the last twelve months, down 10% on a year earlier with a −23% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $270.5M+13% | $276.6M−16% | $300.4M+83% | $254.7M−25% | $293.8M+9% | $194.7M−30% | $222.2M−26% | $140.9M−45% | $231.1M−21% | $148.7M−24% | $156.1M−30% | $234.3M+66% | |
| Cost of revenue | $176.8M+20% | $185.1M−16% | $144.6M−5% | $296.1M+55% | $122.6M−31% | n/a | $88.5M−39% | $66.9M−77% | $85.9M−30% | $84.9M | $72M−19% | $97.1M+45% |
| Gross profit | $93.7M+1% | $91.5M | $155.8M+1267% | −$41.4M | $171.2M+83% | n/a | $133.7M−14% | $74M | $145.2M−15% | $63.8M | $84.1M−37% | $137.2M+85% |
| R&D | $15.3M−64% | $29.4M−49% | $15.1M−63% | $32.7M+26% | $13.8M−10% | $9.1M−69% | $15.1M+0% | $12.5M−62% | $13.5M−2% | $12.1M+33% | $10.5M−31% | $9.2M−26% |
| SG&A | $86M+5% | $89.7M−4% | $84.7M−16% | $85.9M−6% | $76.6M−11% | $60.8M−32% | $52.4M−38% | $43.7M−49% | $38.9M−49% | $51.1M−16% | $46.6M−11% | $44.6M+2% |
| −$242.1M+434% | −$43.8M−21% | $39.8M | −$203.5M−31% | $64.5M | −$9.5M−78% | $49.9M+25% | $1.6M | $76.5M+19% | −$27.9M+194% | $10.5M−79% | −$125.1M | |
| Interest expense | $19.7M+132% | $21.7M+70% | $24.3M+36% | $23.6M−18% | $8.3M−58% | $14.8M−32% | $14.7M−40% | $14.7M−38% | $15.2M+83% | $14.7M−1% | $11M−25% | $10M−32% |
| Pre-tax income | −$265.9M+296% | −$54.5M−24% | $12.1M | −$269.8M+8% | $142.4M | −$27.6M−49% | $92.7M+666% | −$16.8M−94% | $57.6M−60% | −$50.7M+84% | $13.4M−86% | −$166.3M+890% |
| −$2.5M | −$5M | $3.1M−88% | $13.3M+19% | $27.6M | $3.7M | $24.7M+697% | −$4.8M | $6.4M−77% | $3.9M+5% | $6.6M−73% | $13.9M | |
| Net income | −$263.4M+202% | −$49.5M−26% | $9M | −$283.1M+8% | $114.8M | −$31.3M−37% | $68M+656% | −$12M−96% | $51.2M−55% | −$54.6M+74% | $6.8M−90% | −$180.2M+1402% |
| −$5.08+190% | −$0.95−29% | $0.17 | −$5.38+4% | $2.06 | −$0.58−39% | $1.19+600% | −$0.22−96% | $0.91−56% | −$1.04+79% | $0.07−94% | −$3.49+1486% | |
| 51.8M+4% | 52.1M+5% | 52.2M+4% | 52.6M+4% | 55.6M+7% | 54.2M+4% | 57.3M+10% | 54.2M+3% | 56.5M+2% | 52.3M−4% | 56.5M−1% | 51.6M−5% |
Gross profit: 64 periods, Q2 FY10 to Q2 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: 14 periods, Q4 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 9 periods, Q4 FY10 to Q4 FY21: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY11: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution. Q4 FY15: share-days: the 12-month average over 365 days less the 9-month over 273, the two on one basis (x1.224). 5 periods, Q4 FY18 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Emergent BioSolutions' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| EBSEmergent BioSolutions | $319.4M | n/m | 26.0× | 0.4× | −10% | −23.0% | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| ARVNArvinas | $477.3M | 45.6× | 52.3× | 1.5× | −15% | 2.9% | |
| PBYIPuma Biotechnology | $568.9M | 21.2× | 12.3× | 2.5× | −3% | 11.6% | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.9× | 1.5× | +26% | 33.4% | |
| ZVRAZevra Therapeutics | $582.6M | 10.5× | 12.3× | 4.3× | +119% | 42.8% | |
| CRMDCorMedix | $611.9M | 3.7× | 4.0× | 1.3× | +281% | 40.5% | |
| COLLCollegium Pharmaceutical | $747.5M | 18.5× | 19.1× | 0.9× | +14% | 5.9% | |
| ABUSArbutus Biopharma | $831M | 5.4× | 5.6× | 4.6× | n/m | 84.2% | |
| AMPHAmphastar Pharmaceuticals | $1.1B | 14.8× | 20.6× | 1.5× | +1% | 10.8% | |
| OMEROmeros | $1.2B | 10.9× | 11.7× | n/m | n/m | n/m | |
| Peer median | $597.2M | 11.5× | 13.6× | 1.5× | +11% | 11.6% |
More on Emergent BioSolutions
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #2of 199Healthcare stocks with the highest free cash flow yield
- #1of 44Large drugmakers with the highest free cash flow yield
- #9of 48Large drugmakers with the lowest EV/EBIT
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .